• New therapies against cancer

    In 1906, Paul Ehrlich predicted that chemists would soon be able to produce substances that would seek out specific disease-causing agents. He referred to these substances as 'magic bullets'.

At Vivolux we believe in the methodology and creativity of Ehrlich although since his time chemical know-how and the instruments found in pharmaceutical laboratories have advanced considerably. By combining creativity with expert knowledge in organic chemistry, biochemistry, clinical pharmacology, mechanism of action studies and experimental and clinical oncology, Vivolux is playing an active part in developing the magic bullets predicted by Ehrlich. Achieving success in the search for a 'magic bullet' in cancer therapy is now greater than ever.

 

Press releases

  • PRESS RELEASE | May 20, 2016

    Vivolux announced today that dose level 4 of the ongoing VLX600 study has been successfully completed as part of its phase I/II study. Patient enrollment is now expanding to dose level 5, 90 mg of VLX600.

    More
  • PRESS RELEASE | September 17, 2015

    Vivolux, a pharmaceutical company specialized in cancer treatment, announced today that the first patient in its ongoing Phase I/II study has successfully completed treatment at the third dose level of the drug candidate VLX1570.

    More
GO TO NEWS AND PRESS

News

  • NEWS | June 6, 2016

    Nature publication on the anti-cancer mode-of-action of VLX1570

    More
  • NEWS | June 2, 2016

    Memorial Sloan Kettering Cancer Center identifies Vivolux clinical drug candidate VLX1570 as a potential new treatment for Ewing’s sarcoma.

    More
GO TO NEWS AND PRESS
RESEARCH AND DEVELOPMENT AT VIVOLUX

Vivolux’s mission is to explore new therapies against cancer. Our R&D projects are performed in close collaboration with cancer institutes and academia with very encouraging outcomes. 

GO TO R&D PROGRAMS

ONGOING CLINICAL TRIALS AT VIVOLUX

Vivolux's focus and strategy has led to the successful registration of two novel drug candidates. The clinical programs are being run in collaboration with the leading cancer institutes in the USA.

GO TO CLINICAL TRIALS